- Auristone secured $4M in seed funding led by Elev8 for its epigenomics healthcare.
- The biotech startup’s Epi-Call technology predicts cancer treatment responses.
- Auristone aims to scale into new markets and personalized healthcare solutions.
Auristone, a Singapore-based biotech startup, has secured a US$4 million seed funding round led by venture capital firm Elev8.
Seeds Capital, the investment arm of Enterprise Singapore, and existing investor Genedant also participated in the funding.
Aditya Mathur, managing director at Elev8, highlighted Auristone’s ability to profile molecules and predict their medical interactions using epigenomics biomarkers, stating that the human epigenome is the next frontier for unlocking precision healthcare.
Pioneering molecular profiling technology
Auristone’s flagship product, Epi-Call, is a molecular profiling technology that helps predict an individual’s likelihood of response to different cancer treatment options.
The startup’s focus on epigenomics, the science of how genes are expressed, sets it apart in the field of precision healthcare. The newly acquired funding will be used to drive more clinical collaborations and market adoption of Epi-Call.
Scaling into new markets with personalized healthcare
Tan Kaixin, general manager at Seeds Capital, expressed excitement about supporting Auristone as it scales into new markets such as South Korea, Japan, and beyond.
Seeds Capital looks forward to partnering with the Auristone team to further the adoption of epigenomics in genomic testing and create better, personalized healthcare solutions.
To read the original article: https://www.techinasia.com/sg-biotech-startup-snags-4m-seed-funding-elev8-seeds-capital
